ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1485

Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index

guru Vijay Chagalakondu and Vijaya prasanna Parimi, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India

Meeting: ACR Convergence 2025

Keywords: Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition presenting with unpredictable varying levels of severity. Thus, constant monitoring of disease activity is required. The fibrinogen-to-albumin ratio, is an emerging marker which can be used as a cost effective surrogate marker of disease activity in countries with limited resources.

Methods: In a cross-sectional observational study, 63 adult patients with SLE, were included in the study, conducted over a duration of one year, in the Department of Rheumatology, of a tertiary care centre. exclusion criterion included pregnancy, diabetes mellitus, active infections and presence of other autoimmune conditions. Clinical evaluation and laboratory asssessments (including fibrinogen, albumin, ESR, CRP, complements, anti-dsDNA, UPCR, and 24-hour urine protein) were recorded. Disease activity was categorized using SLEDAI-2K as stable, mild, moderate, or severe. FAR was calculated, and its correlation with SLEDAI was assessed using Pearson’s r. Receiver operating characteristic (ROC) analysis determined FAR’s diagnostic accuracy in identifying severe disease.

Results: The cohort was predominantly female (95.2%), with a mean age of 32.2±8.9 years and mean disease duration of 4.9±4.1 years. The mean SLEDAI score was 8.7±5.4; FAR averaged 84.7±40.7. FAR exhibited a strong positive correlation with SLEDAI (r=0.645, p< 0.001). ROC analysis revealed an AUROC of 0.717 (p=0.028) for FAR in identifying severe disease. At a cut-off of ≥95.3, FAR predicted severe SLE with 80% sensitivity, 69% specificity, and an impressive 97.6% negative predictive value

Conclusion: Fibrinogen-to-albumin ratio demonstrates a strong correlation with SLE disease activity and offers moderate diagnostic accuracy in distinguishing severe flares. owing to its cost-effectiveness, it can be used a practical biomarker for SLE disease activity surveillance.

Supporting image 1Fig 1: Comparison of FAR score to predict SLE disease activity.

Supporting image 2Fig 2: Scatter plot of SLEDAI Score and FAR Score in the study cohort.


Disclosures: g. Chagalakondu: None; V. Parimi: None.

To cite this abstract in AMA style:

Chagalakondu g, Parimi V. Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/lupus-under-the-lens-fibrinogen-to-albumin-ratio-as-a-novel-inflammatory-index/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-under-the-lens-fibrinogen-to-albumin-ratio-as-a-novel-inflammatory-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology